MA32029B1 - Vaccins contre la malaria - Google Patents

Vaccins contre la malaria

Info

Publication number
MA32029B1
MA32029B1 MA33034A MA33034A MA32029B1 MA 32029 B1 MA32029 B1 MA 32029B1 MA 33034 A MA33034 A MA 33034A MA 33034 A MA33034 A MA 33034A MA 32029 B1 MA32029 B1 MA 32029B1
Authority
MA
Morocco
Prior art keywords
particle
vaccines against
against malaria
protein
yeasts
Prior art date
Application number
MA33034A
Other languages
Arabic (ar)
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40560235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32029(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32029B1 publication Critical patent/MA32029B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une nouvelle particule protéique, des méthodes de préparation et de purification de ladite particule, son utilisation pour un médicament, en particulier pour la prévention d'infections paludiques, des compositions/vaccins contenant la particule ou des anticorps dirigés contre la particule protéique, tels que des anticorps monoclonaux ou polyclonaux, et leur utilisation, en particulier pour une thérapie. Les particules peuvent en outre être préparées dans un rapport spécifique à l'aide de levures,
MA33034A 2007-12-24 2010-07-19 Vaccins contre la malaria MA32029B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1652507P 2007-12-24 2007-12-24
US1652207P 2007-12-24 2007-12-24
PCT/EP2008/068130 WO2009080803A1 (fr) 2007-12-24 2008-12-22 Vaccins contre la malaria

Publications (1)

Publication Number Publication Date
MA32029B1 true MA32029B1 (fr) 2011-01-03

Family

ID=40560235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33034A MA32029B1 (fr) 2007-12-24 2010-07-19 Vaccins contre la malaria

Country Status (21)

Country Link
US (1) US8999347B2 (fr)
EP (1) EP2234638A1 (fr)
JP (1) JP2011507817A (fr)
KR (1) KR20100111281A (fr)
CN (1) CN101951947A (fr)
AP (1) AP2010005294A0 (fr)
AR (1) AR069936A1 (fr)
AU (1) AU2008339969A1 (fr)
BR (1) BRPI0821531A2 (fr)
CA (1) CA2709041A1 (fr)
CL (1) CL2008003875A1 (fr)
CO (1) CO6300962A2 (fr)
CR (1) CR11585A (fr)
DO (1) DOP2010000186A (fr)
IL (1) IL206311A0 (fr)
MA (1) MA32029B1 (fr)
PE (1) PE20091529A1 (fr)
TW (1) TW200940087A (fr)
UY (1) UY31574A1 (fr)
WO (1) WO2009080803A1 (fr)
ZA (1) ZA201004414B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574239A (en) * 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129461T3 (es) * 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP1846023B1 (fr) * 2005-01-18 2013-09-25 Walter Reed Army Institute of Research Proteine circumsporozoite hybride de plasmodium vivax et son vaccin
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
NZ574239A (en) * 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines

Also Published As

Publication number Publication date
AR069936A1 (es) 2010-03-03
IL206311A0 (en) 2010-12-30
EP2234638A1 (fr) 2010-10-06
AU2008339969A1 (en) 2009-07-02
CR11585A (es) 2010-09-03
AP2010005294A0 (en) 2010-06-30
BRPI0821531A2 (pt) 2015-06-16
CN101951947A (zh) 2011-01-19
PE20091529A1 (es) 2009-10-29
JP2011507817A (ja) 2011-03-10
ZA201004414B (en) 2014-11-26
UY31574A1 (es) 2009-08-03
TW200940087A (en) 2009-10-01
KR20100111281A (ko) 2010-10-14
CA2709041A1 (fr) 2009-07-02
DOP2010000186A (es) 2010-09-30
US20100272788A1 (en) 2010-10-28
US8999347B2 (en) 2015-04-07
CO6300962A2 (es) 2011-07-21
CL2008003875A1 (es) 2010-02-05
WO2009080803A1 (fr) 2009-07-02

Similar Documents

Publication Publication Date Title
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA30671B1 (fr) Vaccins contre le paludisme
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
EA201291366A1 (ru) Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
MA33448B1 (fr) 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamides utilises en tant qu'inhibiteurs de jak
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA34308B1 (fr) Triazolopyridines substituées
MA32646B1 (fr) Compositions d'antagonistes de pd -1 et methodes d'utilisation associees
MA30807B1 (fr) Compositions pharmaceutiques.
MA37610B1 (fr) Formulations de testostérone proliposomales
MA32548B1 (fr) Composition pharmaceutique a base de progesterone micronisee et ses utilisations
EA201390932A1 (ru) ПРОИЗВОДНЫЕ 5,6-ДИГИДРОИМИДАЗО[1,2-а]ПИРАЗИН-8-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ)
MA30478B1 (fr) Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.
MA38260B1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
MA32688B1 (fr) Composes n-sulfonamido pyrazolyles polycycliques
MA37317B1 (fr) Formulation d'anticorps il-17